The Role of GNMT and MMP12 Expression in Determining TACE Efficacy: Validation at Transcription and Protein Levels
Tianhao Cong,Chao Yang,Qi Cao,Jinrui Ren,Yingen Luo,Pei Yuan,Bo Zheng,Yu Liu,Hongcai Yang,Wendi Kang,Aixin Ou,Xiao Li
DOI: https://doi.org/10.2147/jhc.s441179
2024-01-17
Journal of Hepatocellular Carcinoma
Abstract:Tianhao Cong, 1 Chao Yang, 1 Qi Cao, 2 Jinrui Ren, 1 Yingen Luo, 1 Pei Yuan, 2 Bo Zheng, 2 Yu Liu, 1 Hongcai Yang, 1 Wendi Kang, 1 Aixin Ou, 1 Xiao Li 1 1 Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 2 Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China Correspondence: Xiao Li, Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China, Tel +86-13910309111, Fax +86-028-88092354, Email Purpose: Transarterial chemoembolization (TACE) represents a significant therapeutic modality for hepatocellular carcinoma (HCC). We aimed to develop a gene signature to accurately predict patient TACE response and explore the underlying mechanisms. Methods: Three independent datasets were utilized, including GSE104580, GSE14520 and external validation from the Cancer Hospital Chinese Academy of Medical Sciences. GSE104580 was randomly partitioned into a training set and a validation set, whereas GSE14520 was categorized into a resection group and a TACE group. Logistic regression was used to develop a TACE effectiveness model. Immunohistochemistry is utilized to confirm the protein expression trends of the signature genes. Immune infiltration and functional enrichment analyses were conducted to investigate the potential underlying mechanisms. Results: A 2-gene signature consisting of glycine N-methyltransferase (GNMT) and matrix metalloproteinase-12 (MMP12) was constructed, and based on this, all the patients were assigned TACE effectiveness scores and categorized into high effectiveness (HE) and low effectiveness (LE) groups. The HE group exhibited a better prognosis than the LE group in the various cohorts ( p < 0.05). In the external validation set, immunohistochemistry confirmed the expression of the signature genes exhibiting an upregulated trend of GNMT in the HE group and MMP12 in the LE group, the LE group also exhibited a poorer prognosis [for overall survival (OS), HE group: 881 days vs LE group: 273 days ( p < 0.05), and for progression-free survival (PFS), HE group: 458 days vs LE group: 136 days ( p < 0.05)]. Multivariate analysis in all the datasets identified LE status as an independent risk factor for OS, disease-free survival (DFS) and PFS. The infiltration level of M0 macrophages and activated mast cells in the LE group was significantly higher than in the HE group. The hypoxia signaling pathway and glycolysis pathway were significantly enriched in the LE group. Conclusion: The loss of GNMT and the overexpression of MMP12 may be critical factors influencing TACE efficacy. Keywords: hepatocellular carcinoma, transarterial chemoembolization, immune infiltration, mast cell, glucose metabolism, hypoxic microenvironment Primary liver cancer is the sixth most common cancer in the world, with the third highest mortality rate, and hepatocellular carcinoma (HCC) accounts for 75%-80% of primary liver cancers. 1 Currently, the 5-year survival rate of HCC is 18%, one of the key reasons may be the high heterogeneity of HCC. 2,3 Due to this high heterogeneity, even when receiving the same treatment, there are considerable differences in patient outcomes, with several patients still not deriving benefits from the therapy. 4 Therefore, the realization of precision individualized medical care is crucial for improving the prognosis of HCC patients. Transarterial chemoembolization (TACE) is a treatment that leads to localized ischemic necrosis and induces cell death by infusion of embolic agents and chemotherapeutic drugs into the hepatic artery. 5 It is not only a first-line therapy for HCC patients with intermediate stage [Barcelona Clinic Liver Cancer (BCLC)-B stage] disease but also an important platform for downstaging, conversion therapy and combination therapy. 6,7 The overall survival (OS) rate of HCC patients treated with TACE was 70.3% at 1 year, 51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years. 8 However, only a subset of patients exhibited a survival benefit from TACE. 8,9 At present, there are several criteria for evaluating the efficacy of TACE. The modified Respo -Abstract Truncated-
oncology